References
- Aldinucci D, Poletto D, Zaognel V, Rupolo M, Degan M, Nanni P, Gattei V, Pinto A. In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human γδ+ T-cell malignancies. British Journal of Haematology 2000; 110: 188–196
- Catovsky D. Clinical experience with 2′-deoxycoformycin. Hematology and Cell Therapy 1996; 38: S103–S107
- Weidmann E. Hepatosplenic T cell lymphoma. A review of 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991–997
- Arnulf B, Copie-Bergman C, Delfau-Larue M H, Slove Al, et al. Nonhepatosplenic γδ T-cell lymphoma: A subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91: 1723–1731
- Ghura H S, Carmichael A J, Bairstow D, Finney R. Fatal erythroderma associated with pentostatin. British Medical Journal 1999; 319: 549
- Yoe J, Gause B L, Curti B D, Longo D L, Bagg A, Kopp W C, Janik JE. Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin. American Journal of Hematology 1998; 57: 253–257